Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dengue virus non-structural protein 3 (NS3) is a multifunctional enzyme essential for the replication and maturation of the Dengue virus (DENV). It contains two primary functional domains: an N-terminal serine protease that requires the NS2B protein as a cofactor for activity, and a C-terminal region with helicase, nucleoside triphosphatase (NTPase), and RNA triphosphatase (RTPase) activities [1, 2, 4]. The protease domain is responsible for the critical cleavage of the viral polyprotein into functional proteins, while the helicase domain facilitates viral RNA replication by unwinding double-stranded RNA intermediates [3, 9, 13]. As a conserved protein across all four Dengue serotypes and a major target for host cellular immunity, NS3 is a high-priority target for direct-acting antiviral development [1, 11]. Infection by Dengue virus can lead to conditions ranging from self-limiting fever to severe Dengue hemorrhagic fever, making the disruption of NS3-mediated replication a key clinical objective [4, 5]. Current therapeutic efforts involve small-molecule inhibitors designed to disrupt its enzymatic functions or its interactions with other viral proteins like NS4B and NS5 [4, 7, 10].
Competitive or allosteric inhibition of the NS2B-NS3 protease active site to prevent viral polyprotein cleavage; inhibition of the C-terminal helicase domain to block RNA unwinding; disruption of protein-protein interactions between NS3 and cofactors such as NS4B or NS5.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dengue virus non-structural protein 3 (NS3).